

1. The authors aimed to present a summary and review the available published data in this area to help us better understand the emerging role of dual biologic therapy in inflammatory bowel disease. It is a well written article. I would like to suggest some points to further improve the article. - I suggest that authors include the purpose of the article at the end of the introduction. - When the authors cite the randomized controlled trials of combination of biological therapy, the VEGA study - Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study. Gastroenterol Hepatol (N Y). 2022. Apr;18(4 Suppl 1):9-10. PMID: 35610992, was published in the abstract form. It is up to the authors to include this abstract in this article.

Review 1

We have tried to update and include the suggestions, including amending the reference and including the purpose of the article at the end of the introduction.

2. This study aims to present a summary and review the available published data to help us understand the emerging role of dual biologic therapy in inflammatory bowel disease. The authors explore the efficacy and safety of dual biologic therapy in IBD according to different types of studies such as RCT, case report, et al, but it lacks a systematic summary of dual biologic therapy. Therefore, the overall structure appears messy and lacks logic. Regarding the safety of dual biologic therapy, short- and long-term safety needs to be discussed.

Review 2

We have tried to update the article based on the review comments. We have updated the purpose of the article in the introduction to help the reader follow the reasons for outlining the current evidence in the way we have approached it. This is still an emerging area and therefore have tried to provide a summary of what is currently published. There is not significant information regarding long and short term safety at present, we have now acknowledged this in the text.